Abstract 4359074: The Artificial Intelligence-Derived Electrocardiographic Age Gap is Associated with Adverse Clinical Outcomes in Cardiac Laminopathy

M Matteo Castrichini A Agata Sularz (Mayo Clinic, Rochester, Minnesota, United States) R Ramin Garmany D David Tester (Mayo Clinic, Rochester, Minnesota, United States) J Johan Bos (Mayo Clinic, Rochester , Minnesota, United States) Z Zachi Attia (Mayo Clinic, Rochester, Minnesota, United States) P Peter Noseworthy (MAYO CLINIC, Rochester, Minnesota, United States) P Paul Friedman (Mayo Clinic, Rochester, Minnesota, United States) F Francisco Lopez-Jimenez (MAYO CLINIC COLL MEDICINE, Rochester, Minnesota, United States) M Michael Ackerman (Mayo Clinic, Rochester , Minnesota, United States) M Margherita Milone (Mayo Clinic, Rochester, Minnesota, United States) J John Giudicessi (Mayo Clinic, Rochester , Minnesota, United States)

Abstract

Background: Disease-causative variants in LMNA -encoded lamin A/C cause the laminopathies, a heterogeneous group of diseases variably resulting in arrhythmogenic/dilated cardiomyopathy (ACM/DCM), lipodystrophy, muscular dystrophy, and progeria. The artificial intelligence (AI)-derived electrocardiographic age gap (AI-EAG), determined by the discrepancy between a patient’s artificial AI-enabled electrocardiogram (ECG) predicted biological age versus their chronological age, is accelerated in laminopathy. Thus, we sought to determine if the AI-EAG serves as a prognostic marker in patients with cardiac laminopathy. Methods: Retrospective analysis of 1,049 genotype-positive patients with genetic ACM/DCM was used to identify those with pathogenic/likely pathogenic (P/LP) variants in LMNA . After the exclusion of those who lacked a 12-lead ECG while in sinus rhythm, a previously trained AI-ECG age algorithm was used to determine the AI-EAG by subtracting the patient’s chronological age from the AI-ECG derived biological age. The AI-EAG was then correlated with a combined outcome of major ventricular arrhythmia [sudden cardiac arrest, sustained ventricular tachycardia, and appropriate implantable cardioverter-defibrillator shocks], heart transplantation, and cardiovascular death. Results: Overall, 147/1,049 (14%) patients with genetically-mediated ACM/DCM had a P/LP variant in LMNA . Of these, 80/147 (54%) LMNA variant-positive patients (52% female, mean chronological age 36 ± 15 years) had ECGs suitable for AI-EAG analysis. Most (52/80; 65%) had an AI-EAG >10 years with a mean AI-EAG of 17 ± 13 years. Of note, the AI-EAG was greater in those with a clinical cardiac phenotype (20 ± 14 vs. 13 ± 10 years; p = 0.011). As a continuous variable, an increased AI-EAG was associated with increased risk of the composite outcome at a median follow-up of 20 months (HR 1.036; 95% CI 1.004–1.068; p = 0.026) and AI-EAG > 10 and > 20 years were both associated with elevated risk (HR 4.272; 95% CI 1.388–13.147; p = 0.011 and HR 3.732; 95% CI 1.505–9.255; p = 0.004, respectively). Conclusion: In cardiac laminopathy, an increased AI-EAG was common and correlated with adverse cardiovascular outcomes. Non-invasive ascertainment of electrocardiographic aging by AI may provide a novel prognostic marker in cardiac laminopathy. Future studies are needed to validate this finding and further define the role of the AI-EAG in the risk-stratification of patients with cardiac laminopathy.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (12)

M

Matteo Castrichini

A

Agata Sularz

Mayo Clinic, Rochester, Minnesota, United States

R

Ramin Garmany

D

David Tester

Mayo Clinic, Rochester, Minnesota, United States

J

Johan Bos

Mayo Clinic, Rochester , Minnesota, United States

Z

Zachi Attia

Mayo Clinic, Rochester, Minnesota, United States

P

Peter Noseworthy

MAYO CLINIC, Rochester, Minnesota, United States

P

Paul Friedman

Mayo Clinic, Rochester, Minnesota, United States

F

Francisco Lopez-Jimenez

MAYO CLINIC COLL MEDICINE, Rochester, Minnesota, United States

M

Michael Ackerman

Mayo Clinic, Rochester , Minnesota, United States

M

Margherita Milone

Mayo Clinic, Rochester, Minnesota, United States

J

John Giudicessi

Mayo Clinic, Rochester , Minnesota, United States